Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2003
Primary: To determine the duration of use of zoledronic acid in improving Bone mineral density in patients with prostate cancer who are on hormones intermittently. Secondary Objectives: To describe the safety and tolerability at this dose and schedule
Epistemonikos ID: b1e2b74cee35763b79c5fc604031fefca466b853
First added on: May 04, 2024